Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

29.83 -0.24 (-0.80%)
Official Closing Price Updated: 7:00 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 27,055,359
Open 30.05
Bid (Size) 29.79 (1)
Ask (Size) 29.80 (1)
Prev. Close 30.07
Today's Range 29.60 - 30.14
52wk Range 25.20 - 34.12
Shares Outstanding 5,606,688,356
Dividend Yield 5.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer Unusual Options Activity
Via Benzinga
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire

Performance

YTD
+0.34%
+0.34%
1 Month
+3.58%
+3.58%
3 Month
+8.83%
+8.83%
6 Month
+7.96%
+7.96%
1 Year
-11.33%
-11.33%

More News

Read More
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Via The Motley Fool
Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns
Via Talk Markets
Intel, Microsoft, Meta Platforms, Pfizer, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Beyond The Numbers: 13 Analysts Discuss Pfizer Stock
Via Benzinga
Is Pfizer's 5.7% Dividend Yield Worth the Risk?
Via The Motley Fool
Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.
Via The Motley Fool
Topics Supply Chain
Exposures Supply Chain
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Via Benzinga
Exposures COVID-19
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Via Newsfile
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
From Pfizer Inc.
Via Business Wire
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
From Pfizer Inc.
Via Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
Via Investor's Business Daily
Got $5,000? 3 Dirt Cheap Stocks to Buy Right Now
Via The Motley Fool
Should You Buy Novavax Stock After This Regulatory Win?
Via The Motley Fool
A Bull Market Is Here: 2 High-Potential Stocks Down More Than 50% to Buy Right Now
Via The Motley Fool
Alnylam Stock Soars 65%: Find Out What’s Behind the Gains
Via MarketBeat
Exposures Product Safety
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
Via Benzinga
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
Via Benzinga
Is Hims & Hers Health the Next Teladoc?
Via The Motley Fool
Exposures COVID-19
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
From Pfizer Inc.
Via Business Wire
2 Beaten-Down Stocks That Could Be Great Buys on the Dip
Via The Motley Fool
3 High-Yield Stocks to Buy Hand Over Fist in September
Via The Motley Fool
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.